Introduction

Continuous glucose monitoring (CGM) has revolutionized how people track blood sugar, offering real‑time feedback beyond traditional fingersticks. By wearing a small sensor that measures interstitial glucose every few minutes, you gain rich data on trends, spikes, and “hidden” highs and lows—helping you and your care team fine‑tune diet, exercise, and medications for better metabolic health. In this guide, we’ll demystify CGM technology, explain how to interpret your data, and share practical tips to make the most of your CGM system. 📈

---

🧐 How CGM Technology Works

A CGM system consists of three components: a sensor inserted under the skin, a transmitter that sends data wirelessly, and a receiver or smart device app that displays glucose readings. The sensor uses an enzyme (usually glucose oxidase) to oxidize glucose in the interstitial fluid, producing an electrical current proportional to glucose concentration.

Unlike finger‑stick meters that measure capillary blood at single time points, most prescription CGMs record glucose every 1–5 minutes—288 to 1,440 readings per day. This continuous stream reveals patterns such as dawn phenomenon, nocturnal hypoglycemia, or post‑meal spikes that a single fingerstick or an A1c test can miss (Danne et al., 2017).

---

🔧 Types of CGM Systems

• Real‑time CGM (rtCGM): Continuously streams data to a dedicated receiver or smartphone app, with customizable alerts for high and low glucose. Most prescription CGMs now work this way, including current FreeStyle Libre sensors (ADA, 2026).
• Intermittently scanned CGM (isCGM): Requires scanning the sensor with a reader or smartphone to view current and historical glucose data (e.g., older FreeStyle Libre models).
• Over‑the‑counter (OTC) CGM: Available without a prescription since 2024, when the FDA cleared Dexcom Stelo (FDA, 2024) and Abbott Lingo (Abbott, 2024). They’re for adults who don’t use insulin and have no low‑glucose alarms, so they aren’t meant for people prone to problematic lows.
• Professional CGM: Worn temporarily (7–14 days) under supervision; data downloaded by clinicians to assess patterns without real‑time alerts.

CGM has improved glycemic outcomes in randomized trials. A 2025 meta‑analysis of 64 trials found rtCGM lowered A1c by about 0.2 percentage points in type 1 diabetes and 0.4 in type 2 diabetes versus fingerstick monitoring, while raising time in range and, in type 1 diabetes, cutting time spent in hypoglycemia (Rizos et al., 2025). The American Diabetes Association recommends CGM for people with diabetes who use insulin or other medicines that can cause lows, and for anyone with diabetes whose management it helps (ADA, 2026).

---

📈 Key Benefits for Metabolic Health

• A1c reduction: In randomized trials, rtCGM users lowered A1c by roughly 0.2–0.4 percentage points more than people using fingersticks (Rizos et al., 2025).
• Hypoglycemia prevention: In a 26‑week randomized trial in type 1 diabetes, rtCGM roughly halved time spent below 63 mg/dL compared with fingerstick monitoring (Battelino et al., 2011).
• Behavioral insights: Instant feedback on meal and exercise impacts fosters better dietary and activity choices.
• Time-in-range (TIR): Percent time between 70–180 mg/dL is linked to complication risk. In fingerstick data from the landmark DCCT trial, each 10‑percentage‑point drop in TIR was associated with a 64% higher rate of retinopathy progression and 40% higher rate of microalbuminuria. TIR complements A1c rather than replacing it (Beck et al., 2019).

---

📊 Interpreting Your CGM Data

Modern CGM platforms provide standardized reports—like Ambulatory Glucose Profiles (AGP)—that summarize the following (consensus goals for most adults with type 1 or type 2 diabetes in parentheses) (Battelino et al., 2019):

• Time-in‑range: Percentage of readings within target, 70–180 mg/dL (goal >70%).
• Time‑above‑range: Percent >180 mg/dL, hyperglycemia (goal <25%).
• Time‑below‑range: Percent <70 mg/dL, hypoglycemia (goal <4%, and <1% below 54 mg/dL).
• Glucose variability: Measured by coefficient of variation (CV); goal CV ≤36%.

Goals are looser for older or high‑risk adults (e.g., TIR >50%, under 1% below 70 mg/dL) and different in pregnancy. Review your AGP regularly (about 14 days of data gives a reliable picture) to identify patterns:

• Morning spikes: Could signal dawn phenomenon or, if you use insulin, a basal dose worth reviewing with your care team.
• Post‑meal excursions: Suggest looking at meal composition and portions; if you take mealtime insulin, discuss timing with your clinician.
• Nocturnal lows: Raise these with your care team promptly; an evening snack or a change to your insulin plan may help.

---

📝 Practical Tips for CGM Users

• 🔄 Calibrate if needed: Most current sensors are factory‑calibrated, but a few require finger‑stick calibrations; follow manufacturer guidelines.
• ⏰ Check trends, not single readings: Use trend arrows, alongside your care plan, to guide treatment decisions.
• 🍏 Pair with a food log: Note meals, portions, and timing to correlate with glucose patterns.
• 🚶‍♀️ Track activity: Log exercise sessions to see their immediate effects on glucose.
• 📱 Leverage alerts: On prescription CGMs, set high/low thresholds and trend‑rate alarms to catch dangerous swings early.

---

🚧 Limitations & Considerations

While CGM is powerful, be aware of:

• Lag time: Interstitial glucose trails blood glucose, so readings can differ most when glucose is rising or falling quickly (ADA, 2026).
• Sensor errors: Compression lows (when lying on the sensor), hydration status, and some medications or supplements can skew readings; check your device’s list of interfering substances.
• Cost & access: CGM supplies and sensors may not be fully covered by insurance. When continuous use isn’t feasible, the ADA suggests periodic personal or professional CGM as an option (ADA, 2026).

---

📲 Integrate CGM with Helsa

To put CGM insights in context with diet, activity, and lab results, an app like Helsa can help. Helsa doesn’t measure glucose: it lets you log meals by photo or voice with AI nutrition analysis, analyzes your blood markers, works with wearables like Apple Health, and adds daily reports, a holistic metabolic score, and an AI health coach. It’s free to download on iOS and Android, and no CGM is needed—see how to lower blood sugar without a CGM.

---

Key Takeaways ✅

• Prescription CGMs typically record 288–1,440 readings a day, revealing patterns that fingersticks and A1c can miss.
• Time‑in‑range (goal >70% for most adults with diabetes) and variability are important metrics alongside A1c.
• Use AGP reports to adjust meals and activity, and review any insulin or medication changes with your care team.
• Be mindful of sensor lag and potential errors; check with a meter when a reading doesn’t match how you feel.
• The ADA recommends CGM for people on insulin; OTC options now exist for adults who don’t use insulin.
• Pair CGM insights with lifestyle and lab tracking in an app like Helsa for personalized insights.

---

References

• Danne T. et al. “International Consensus on Use of Continuous Glucose Monitoring” (2017)
• American Diabetes Association. “7. Diabetes Technology: Standards of Care in Diabetes—2026” (2026)
• U.S. FDA. “FDA Clears First Over‑the‑Counter Continuous Glucose Monitor” (2024)
• Abbott. “Abbott Receives U.S. FDA Clearance for Two New Over‑the‑Counter Continuous Glucose Monitoring Systems” (2024)
• Rizos EC. et al. “Continuous Glucose Monitoring in Type 1 Diabetes, Type 2 Diabetes, and Diabetes During Pregnancy: A Systematic Review with Meta‑Analysis of Randomized Controlled Trials” (2025)
• Battelino T. et al. “Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes” (2011)
• Beck RW. et al. “Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials” (2019)
• Battelino T. et al. “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range” (2019)